# SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

> **NCT07451795** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 66 (estimated)

## Conditions studied

- Prostate Cancer
- mCRPC (Metastatic Castration-resistant Prostate Cancer)

## Interventions

- **COMBINATION_PRODUCT:** SHR-1701 + SBRT
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT07451795
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07451795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07451795, "SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07451795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*